10 Big Names Crushing Wall Street

7. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BridgeBio rallied for a third straight day on Monday to hit a new all-time high as investors snapped up shares following the stellar results of its final clinical trial for the study of BBP-418 in patients with a rare genetic condition that causes muscles to weaken, affects breathing problems, and causes heart issues.

In intra-day trading, the stock surged to its highest price of $65 before trimming gains to end the day just up by 17.14 percent at $63.56 apiece.

In a statement, BridgeBio Pharma, Inc. (NASDAQ:BBIO) said its drug candidate, BBP-418, showed major improvements in muscle and lung function in patients during the phase 3 clinical trial.

Among the salient results are the restoration of a key muscle protein often missing in individuals with the said disease and enabling patients to walk faster and have a better lung capacity, as compared with those who took the placebo.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) added that BBP-418 was well-tolerated with no major safety findings observed.

Following the results, BridgeBio Pharma, Inc. (NASDAQ:BBIO) is set to meet with the Food and Drug Administration by the end of the year to discuss the data. A New Drug Application is targeted for submission within the first half of 2026.